menu

Quintiles Library

Precision Enrollment
Featured Video
Show Filters
Article
PharmaBoardroom Q&A with Anand Tharmaratnam, President of QuintilesIMS Asia Pacific, about life-sciences in Asia Pac and Singapore's role as a hub for the region.
Explore More
Presentation
Over the past 30 years, our greatest accomplishments in advancing understanding about the safety, effectiveness and value of healthcare interventions have been achieved through the studying of health records for large populations. More recently, access to electronic health records and other electronic data that can be linked or supplemented by other critical information...
Explore More
Presentation
Risk-based monitoring, and its increasing awareness, is widely viewed as a clinical strategy contributing to better quality control, data accuracy and lower costs. The core of risk-based monitoring is Centralized Monitoring, which has evolved through three stages or “waves,” with value increasing at each wave. QuintilesIMS has built and recently launched a technology...
Explore More
White Paper
The dramatic increase in the amount of digitized healthcare information being generated brings new opportunity to close the “healthcare gap” – the difference between today’s reality and what is possible from a clinical, patient and economic perspective. Appropriately accessing and utilizing information for research purposes is a critical element of closing this gap. In...
Explore More
White Paper
Risk-based monitoring, and its increasing awareness, is widely viewed as a clinical strategy contributing to better quality control, data accuracy and lower costs. The core of risk-based monitoring is Centralized Monitoring, which has evolved through three stages or “waves,” with value increasing at each wave. QuintilesIMS has built and recently launched a technology...
Explore More
Infographic
QuintilesIMS Continuous Glucose Monitoring offers a more complete view of the daily measures of glucose levels and variability than the traditional measures of glucose control by self-monitored blood glucose (SMBG) and HbA1c, promoting enhanced patient safety and clinical outcomes. Our innovative platform – combined with leading operational and therapeutic expertise –...
Read More
White Paper
下一代测序技术将为肿瘤临床试验和癌症治疗带来革新
Explore More
Fact Sheet
QuintilesIMS Solution Design Studio offers an interactive, visual approach to defining and designing technology solutions. By allowing your stakeholders to experience proposed solutions from the beginning, we can envision optimal outcomes together. Digital simulation, user interface design and proven early-development process help drive on-target innovation and rapid...
Read More
White Paper
This insight brief examines the varied definitions and regulatory pathways for rare disease therapies. The authors describe QuintilesIMS’s proven patient centric approaches to study planning, innovative ways to accelerate patient recruitment through an efficient site strategy, and the importance of real-world evidence.
Explore More
Brochure
Managing long term conditions is challenging, for both patients and the healthcare system. Getting patients more involved in their care through patient support programs can help improve their outcomes and take the pressure off the healthcare system. Gain an understanding of why programs need to be tailored specifically to the patient, disease type and its stage. Learn...
Read More
Brochure
Getting a drug through clinical trials and successfully on to the market after regulatory approval is a long process, and it might be understandable for a company to metaphorically take a moment to catch its breath. Approval, however, is only the first step; the next big hurdle is to get the best positioning and market access for the drug, so that the right patients can...
Read More
White Paper
The future of medicine rests on data: the evidence that is the basis for the discovery, development and dispensing of prescription products and all other healthcare decisions. Data, and the analysis of that data, informs drug development, portfolio decisions, prescribing behaviors, patient compliance and reimbursement policy in value-based healthcare systems. Mastering...
Explore More
White Paper
Multiple myeloma is an extremely complex genomic disease that accounts for 1% of all cancers and 13% of all hematologic malignancies. Worldwide, approximately 86,000 new cases occur annually. Recently, clinical research in multiple myeloma has been very active, and various novel therapies are being investigated. This White Paper addresses several important components of...
Explore More
Presentation
Today’s diabetes clinical development landscape is competitive, complex, and in demand. Continuous Glucose Monitoring (CGM) has the potential to become the new gold-standard in diabetes clinical trials. CGM provides more robust glycemic data sets and glucose variability than ever before, which leads to better clinical outcomes and patient safety. Navigating and...
Explore More
Presentation
Drug development challenges drive the need to translate scientific and therapeutic advances to better outcomes. As such, developing the evidence you need to meet the needs of all stakeholders, including investors, regulators, payers, providers and patients, and proving value in the real-world becomes critical.In this webinar, QuintilesIMS experts Laura Marquis, John Doyle...
Explore More
White Paper
Developing complex generics to adapt to a challenging drug development processGenerics have been an attractive, lucrative development path for more than three decades. As the market has become saturated with simple generic products, biopharma companies are turning their focus to complex generic drugs, which deliver more value to patients by addressing additional unmet...
Explore More
Fact Sheet
For success in early clinical development, it’s critical to find the right participants, target dose/exposure, response and commercial strategy. A tailored delivery model that is proactive and scalable can help you meet these challenges – and accelerate your Phase I trial or program. Improve your probability of success with QuintilesIMS’s global drug development...
Read More
Presentation
As a senior leader in emerging biopharma, you know that examining your product development program through the lens of all stakeholders is critical for success. But are you clear on key metrics and milestones your key investors are seeking? Are you taking the appropriate steps in early clinical development to lay the groundwork for these metrics and navigate your clinical...
Explore More
White Paper
Epilepsy – which poses a serious burden for patients, with effects on quality of life, work productivity, healthcare needs and risk of premature death – is diagnosed in some 2.4 million people globally each year, and currently affects around 300,000 American children under the age of 14. Pediatric epilepsies present particular challenges, including correct diagnoses,...
Explore More
White Paper
QuintilesIMS authors, along with members of the Clinical Operations Group at the Sarah Cannon Research Institute, collaborated in writing this White Paper entitled “Managing Multi-Arm Studies in an Evolving Immuno-Oncology Landscape.”  Immunotherapy is a treatment strategy that targets the host immune system, not the tumor itself.  Early successes have led to much...
Explore More